Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.14) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14), Bloomberg Earnings reports.
Shares of Ritter Pharmaceuticals (RTTR) opened at 0.60 on Friday. The firm’s market cap is $8.85 million. Ritter Pharmaceuticals has a 12-month low of $0.50 and a 12-month high of $3.75. The company has a 50 day moving average price of $0.57 and a 200-day moving average price of $1.33.
Several analysts have commented on the company. Maxim Group reaffirmed a “hold” rating on shares of Ritter Pharmaceuticals in a research note on Friday, August 4th. Zacks Investment Research upgraded Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a report on Thursday, August 10th. Finally, Chardan Capital lowered their price target on Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating on the stock in a report on Tuesday, August 8th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $4.88.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.